Items tagged with Treatment
As patients challenge patent, J&J commits to tackling drug-resistant TB (post)
Johnson & Johnson has tripled its commitment on tuberculosis drug Bedaquiline by offering 90,000 doseages to its global donation programme that ends in March, Paul Stoffels, J&J’s Vice-Chair of the Executive Committee and Chief Scientific Officer, said, on a programme that has given medicines to India as well.
India’s drug-resistant TB patients face delayed and confusing diagnoses, treatment (post)
Mumbai: Drug-resistant tuberculosis (DR-TB) patients in India face delayed diagnoses, different treatment pathways from both public and private health care systems and differing costs for the same treatments from different providers in an unregulated private health care sector, says a January 2019 study published in Public Library of Science (PLOS), a scientific journal.
Smartphones help patients complete TB treatment (post)
Patients with tuberculosis (TB) are more likely to continue their drug treatment if they are supported by smartphones rather than attending face-to-face appointments, a new UCL-led study has found.
Weight-age score predicts effectiveness of childhood TB therapy (post)
Weight change early in therapy predicted outcomes of childhood tuberculosis therapy, according to study results published in the Journal of the Pediatric Infectious Diseases Society.
CROI 2019: Study demonstrates cardiac safety of bedaquiline plus delamanid for MDR-TB (post)
SEATTLE — Phase 2 study data presented at CROI demonstrated the cardiac safety of the combined use of bedaquiline and delamanid — two novel tuberculosis medications — in patients with multidrug-resistant TB receiving multidrug background treatment.
TB medicine pretomanid enters regulatory review process in the United States (post)
NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the treatment of extensively drug-resistant (XDR) TB, treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.
Effect of vitamin D supplementation on sputum culture conversion in TB (post)
As a whole, vitamin D supplementation did not affect sputum culture conversion in patients with pulmonary tuberculosis (TB), but in the subgroup of patients with multidrug-resistant TB, vitamin D supplementation did accelerate sputum culture conversion, according to a meta-analysis published in European Respiratory Journal.
Diagnosing chronic pulmonary aspergillosis in treated pulmonary TB (post)
Chronic pulmonary aspergillosis complicates treated pulmonary tuberculosis (TB) frequently enough to represent an unrecognized global public health issue, according to a study published in the European Respiratory Journal.
CROI 2019: Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity (post)
Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.
Final STREAM Stage 1 trial results published (post)
The final results from the STREAM Stage 1 trial, which compared 9-11 months of standardized treatment using older drugs (the so-called modified "Bangladesh" regimen) to the 2011 World Health Organization (WHO)-recommended treatment, were published in the New England Journal of Medicine.
Page 46 of 108 · Total posts: 0
←First 45 46 47 Last→